Dr. Claudio Ronco to discuss his analysis on the importance of endotoxin removal
TORONTO, Oct. 29, 2014 /CNW/ - Spectral Diagnostics Inc. ("Spectral" or the "Company") (TSX: SDI) (OTC QX: DIAGF) a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that it will be an exhibitor at the Critical Care Canada Forum being held at the Sheraton Centre Hotel from October 29 to November 1, 2014.
The Forum is most relevant to individuals involved with care of critically ill patients and focuses on leading-edge science through informative and interactive sessions, outstanding international faculty, poster presentations and more than 50 exhibits, including Spectral Diagnostics, with the latest products and services for the critical care professional.
Dr. Claudio Ronco, a supporter of Spectral's theranostic approach to treating patients with septic shock, will be a key guest speaker discussing "The Future is Endotoxin Removal" on Saturday, November 1, 2014 at 8:50 a.m. ET. Professor Ronco is a director of the Department of Nephrology and the International Renal Research Institute (IRRIV) of San Bortolo Hospital, Vicenza, Italy. He is also considered a pioneer in many areas of nephrology including peritoneal dialysis, acute kidney injury, critical care nephrology, renal replacement therapy, cardiorenal syndromes and wearable dialysis technology.
About Spectral Diagnostics Inc.
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of endotoxemic septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, a main trigger of sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study in the area of septic shock.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with septic shock in North America each year, representing a greater than $2 billion market opportunity for Spectral.
Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTCQX under the symbol DIAGF. For more information please visit www.spectraldx.com
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
SOURCE: Spectral Diagnostics Inc.
For further information: Spectral Diagnostics Inc., Anthony Businskas, Executive Vice President and CFO, 416-626-3233 ext. 2200; Ali Mahdavi, Capital Markets & Investor Relations, 416-962-3300, email@example.com